ArticleFrontiers in pediatrics2026
Median effective dose of intravenous nalmefene for preventing sufentanil-induced cough in children aged 1-6 years: a prospective randomized controlled trial.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sufentanil-induced cough (SIC) during anesthetic induction carries greater risks in young children than in adults owing to their limited functional residual capacity and elevated oxygen demand. No optimal prophylactic dose of intravenous nalmefene has been established for this age group. We aimed to determine the median effective dose (ED50) of nalmefene for preventing SIC in children aged 1-6 years. Methods: In this prospective, randomized, double-blind, placebo-controlled trial (ChiCTR2500111207), 249 children aged 1-6 years undergoing elective laparoscopic surgery were assigned 1:1:1:1 to normal saline (Group A) or nalmefene 0.025, 0.05, or 0.1 μg/kg (Groups B, C, and D), each administered one minute before sufentanil 0.2 μg/kg. The primary endpoint was SIC incidence within one minute of sufentanil injection. The ED50 was estimated using a three-parameter sigmoidal Emax model with bootstrap confidence intervals. Results: SIC incidence declined dose-dependently: 45.9% (Group A), 38.1% (Group B), 30.2% (Group C), and 11.3% (Group D). Groups A vs. D and B vs. D differed significantly (both Conclusions: Intravenous nalmefene prevents SIC dose-dependently in children aged 1-6 years. The ED50 of 0.064 μg/kg provides a clinically applicable reference dose that preserves hemodynamic stability and postoperative analgesia. Trial registration: Chinese Clinical Trial Registry, ChiCTR2500111207 (prospectively registered 25 February 2025).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.